Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives $43.00 Consensus Price Target from Brokerages

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $43.00.

LYEL has been the subject of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $44.00 target price on shares of Lyell Immunopharma in a report on Thursday. Robert W. Baird set a $49.00 target price on shares of Lyell Immunopharma and gave the company an “outperform” rating in a report on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Tuesday, April 21st. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Sunday. Finally, Citizens Jmp initiated coverage on shares of Lyell Immunopharma in a report on Monday, March 9th. They issued a “market outperform” rating and a $34.00 target price for the company.

Lyell Immunopharma Price Performance

Shares of LYEL opened at $19.33 on Tuesday. The company has a 50 day simple moving average of $22.19 and a two-hundred day simple moving average of $23.52. Lyell Immunopharma has a 1 year low of $7.65 and a 1 year high of $45.00. The firm has a market cap of $450.97 million, a P/E ratio of -1.40 and a beta of -0.05.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Wednesday, May 6th. The company reported ($1.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.10). Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 84.36%. The firm had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.00 million. On average, sell-side analysts anticipate that Lyell Immunopharma will post -10.45 earnings per share for the current year.

Insider Activity at Lyell Immunopharma

In related news, COO Stephen J. Hill sold 1,236 shares of the firm’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $28,910.04. Following the completion of the transaction, the chief operating officer directly owned 17,795 shares of the company’s stock, valued at approximately $416,225.05. This trade represents a 6.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Lynn Seely sold 7,455 shares of the firm’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $174,372.45. Following the completion of the transaction, the chief executive officer directly owned 74,266 shares of the company’s stock, valued at approximately $1,737,081.74. This trade represents a 9.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 11,310 shares of company stock valued at $264,285. 6.20% of the stock is owned by corporate insiders.

Institutional Trading of Lyell Immunopharma

Institutional investors have recently bought and sold shares of the stock. BBR Partners LLC bought a new stake in Lyell Immunopharma in the fourth quarter worth $210,000. ExodusPoint Capital Management LP bought a new stake in Lyell Immunopharma in the fourth quarter worth $262,000. Marshall Wace LLP bought a new stake in Lyell Immunopharma in the second quarter worth $94,000. Jane Street Group LLC bought a new stake in Lyell Immunopharma in the fourth quarter worth $382,000. Finally, Barclays PLC lifted its position in Lyell Immunopharma by 1,239.5% in the fourth quarter. Barclays PLC now owns 15,967 shares of the company’s stock worth $491,000 after buying an additional 14,775 shares during the last quarter. 66.05% of the stock is currently owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.